TB Reach
- Home
- TB Reach
Project Setting
In 2021 – 2023, UZT was among recipients of the Stop TB Partnership Wave 9 funding awarded to 11 projects across 8 countries, focusing on innovative approaches to address Drug Resistant TB (DR-TB).
With support from USAID and Global Affairs Canada, the investments support scale-up of newer and shorter all-oral regimens for DR-TB, through the introduction of Xpert MTB/XDR assay for early detection of second-line drug resistance.
In Zimbabwe, the project had footprint in 19 high burden districts across Bulawayo, Matebeleland South and Midlands provinces, with a buy-in of US$600 000 over the 2-year project life-span.
- Project Title: Optimizing SHORRT in Zimbabwe
- Project Goal: To treat all people with DR-TB
- Objectives
- To provide DST for FQ to at least 90% of patients detected with MDR/RR-TB
- To enroll at least 183 (100%) detected DR-TB patients on treatment
- To enroll at least 165 (90%) DR-TB patients on an all oral regimen
- To ensure a treatment success rate of at least 80% among DR-TB patients initiating treatment
The project was implemented in Bulawayo, Midlands and Matabeleland South provinces, which, at that time, contributed two thirds of national case load for DR-TB.
